| Literature DB >> 28874594 |
Patrick A Brown, Bijal Shah, Amir Fathi, Matthew Wieduwilt, Anjali Advani, Patricia Aoun, Stefan K Barta, Michael W Boyer, Teresa Bryan, Patrick W Burke, Ryan Cassaday, Peter F Coccia, Steven E Coutre, Lloyd E Damon, Daniel J DeAngelo, Olga Frankfurt, John P Greer, Hagop M Kantarjian, Rebecca B Klisovic, Gary Kupfer, Mark Litzow, Arthur Liu, Ryan Mattison, Jae Park, Jeffrey Rubnitz, Ayman Saad, Geoffrey L Uy, Eunice S Wang, Kristina M Gregory, Ndiya Ogba.
Abstract
The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management.Entities:
Mesh：
Year: 2017 PMID： 28874594 DOI： 10.6004/jnccn.2017.0147
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908